Annexon Files European MAA for GBS Therapy, Anticipates Pivotal Phase 3 Data for Dry AMD in H2 2026

summarizeSummary

Annexon, Inc. announced its 2026 strategic priorities, including the filing of a Marketing Authorization Application in Europe for its GBS therapy, tanruprubart, and the expectation of pivotal Phase 3 data for its dry AMD therapy, vonaprument, in the second half of 2026. The company also highlighted a strong financial position extending into late 2027.

check_boxKey Events

• European MAA Filed for GBS Therapy

  Annexon has filed a Marketing Authorization Application (MAA) with the European Medicines Agency for tanruprubart, its lead program for Guillain-Barré Syndrome (GBS), with a U.S. BLA submission planned for 2026.

• Pivotal Phase 3 Data Expected for Dry AMD

  Topline data from the pivotal Phase 3 ARCHER II trial for vonaprument in dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) is anticipated in the second half of 2026.

• Oral C1 Inhibitor POC Data

  Proof-of-concept data for ANX1502, an oral C1 inhibitor for autoimmune conditions, is expected in 2026.

• Extended Financial Runway

  The company reported a strong financial position, funding operations into late 2027, well beyond the anticipated key clinical milestones.

auto_awesomeAnalysis

This 8-K signals significant progress across Annexon's lead clinical programs, providing multiple potential catalysts for the stock in 2026. The European MAA filing for tanruprubart is a major regulatory step towards commercialization for Guillain-Barré Syndrome, with a U.S. BLA submission also planned. The upcoming topline Phase 3 data for vonaprument in dry AMD with geographic atrophy represents a critical inflection point, with the potential to establish a new standard of care. Additionally, the company's extended financial runway into late 2027 provides stability and reduces near-term financing concerns, allowing focus on these key development milestones. Investors should monitor the progress of these regulatory submissions and clinical trial readouts closely.